
Stephen G Ellis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/593386/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease. New England Journal of Medicine, 2004, 350, 221-231.	13.9	2,601
2	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2011, 58, e44-e122.	1.2	2,027
3	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Circulation, 2011, 124, e574-651.	1.6	1,946
4	Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents. New England Journal of Medicine, 2007, 356, 998-1008.	13.9	1,776
5	Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet, The, 2003, 362, 697-703.	6.3	1,199
6	Marked Inflammatory Sequelae to Implantation of Biodegradable and Nonbiodegradable Polymers in Porcine Coronary Arteries. Circulation, 1996, 94, 1690-1697.	1.6	726
7	Localized Intracoronary Gamma-Radiation Therapy to Inhibit the Recurrence of Restenosis after Stenting. New England Journal of Medicine, 2001, 344, 250-256.	13.9	608
8	Facilitated PCI in Patients with ST-Elevation Myocardial Infarction. New England Journal of Medicine, 2008, 358, 2205-2217.	13.9	596
9	Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. New England Journal of Medicine, 2015, 373, 1905-1915.	13.9	554
10	Relationship Between Delay in Performing Direct Coronary Angioplasty and Early Clinical Outcome in Patients With Acute Myocardial Infarction. Circulation, 1999, 100, 14-20.	1.6	532
11	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. Circulation, 2011, 124, 2574-2609.	1.6	500
12	Effect of Intracoronary Delivery of Autologous Bone Marrow Mononuclear Cells 2 to 3 Weeks Following Acute Myocardial Infarction on Left Ventricular Function. JAMA - Journal of the American Medical Association, 2011, 306, 2110.	3.8	377
13	Bare metal stent restenosis is not a benign clinical entity. American Heart Journal, 2006, 151, 1260-1264.	1.2	367
14	Significance of Mild Transient Release of Creatine Kinase–MB Fraction After Percutaneous Coronary Interventions. Circulation, 1996, 94, 1528-1536.	1.6	305
15	1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet, The, 2016, 387, 1277-1289.	6.3	253
16	Paclitaxel-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal Stents. JAMA - Journal of the American Medical Association, 2006, 295, 1253.	3.8	243
17	Incremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention. Circulation, 2001, 104, 992-997.	1.6	241
18	Long-Term Clinical Outcomes After Unprotected Left Main Trunk Percutaneous Revascularization in 279 Patients. Circulation, 2001, 104, 1609-1614.	1.6	217

#	Article	IF	CITATIONS
19	Death Following Creatine Kinase-MB Elevation After Coronary Intervention. Circulation, 2002, 106, 1205-1210.	1.6	204
20	Emergency Coronary Artery Bypass Surgery in the Contemporary Percutaneous Coronary Intervention Era. Circulation, 2002, 106, 2346-2350.	1.6	195
21	Contemporary Percutaneous Treatment of Unprotected Left Main Coronary Stenoses. Circulation, 1997, 96, 3867-3872.	1.6	182
22	Offsetting Impact of Thrombosis and Restenosis on the Occurrence of Death and Myocardial Infarction After Paclitaxel-Eluting and Bare Metal Stent Implantation. Circulation, 2007, 115, 2842-2847.	1.6	162
23	Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: The multicenter U.S. Palmaz-Schatz stent experience. Journal of the American College of Cardiology, 1995, 26, 704-712.	1.2	161
24	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. Catheterization and Cardiovascular Interventions, 2012, 79, 453-495.	0.7	157
25	Angiographic Surrogate End Points in Drug-Eluting Stent Trials. Journal of the American College of Cardiology, 2008, 51, 23-32.	1.2	153
26	Correlates and outcomes of retroperitoneal hemorrhage complicating percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2006, 67, 541-545.	0.7	151
27	Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation. Journal of the American College of Cardiology, 2005, 45, 1193-1200.	1.2	149
28	Insights Into Timing, Risk Factors, and Outcomes of Stroke and Transient Ischemic Attack After Transcatheter Aortic Valve Replacement in the PARTNER Trial (Placement of Aortic Transcatheter) Tj ETQq0 0 0	rgB T./ Over	loc 1 24150 Tf 50
29	A Polymorphism in the Protease-Like Domain of Apolipoprotein(a) Is Associated With Severe Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2030-2036.	1.1	143
30	Identification of Four Gene Variants Associated with Myocardial Infarction. American Journal of Human Genetics, 2005, 77, 596-605.	2.6	142
31	Impact of Routine Angiographic Follow-Up on the Clinical Benefits of Paclitaxel-Eluting Stents. Journal of the American College of Cardiology, 2006, 48, 32-36.	1.2	134
32	Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. European Heart Journal, 2018, 39, 1726-1735a.	1.0	133
33	Low-Normal or Excessive Body Mass Index: Newly Identified and Powerful Risk Factors for Death and Other Complications With Percutaneous Coronary Intervention. American Journal of Cardiology, 1996, 78, 642-646.	0.7	130
34	Influence of Transcatheter Aortic Valve Replacement Strategy and Valve Design onÂStroke After Transcatheter Aortic ValveÂReplacement. Journal of the American College of Cardiology, 2014, 63, 2101-2110.	1.2	123
35	Impact of mitral regurgitation on long-term survival after percutaneous coronary intervention. American Journal of Cardiology, 2002, 89, 315-318.	0.7	122
36	Long-Term Safety and Efficacy With Paclitaxel-Eluting Stents. JACC: Cardiovascular Interventions, 2009, 2, 1248-1259.	1.1	122

#	Article	IF	CITATIONS
37	Incidence, Timing, and Correlates of Stent Thrombosis With the Polymeric Paclitaxel Drug-Eluting Stent. Journal of the American College of Cardiology, 2007, 49, 1043-1051.	1.2	121
38	Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. American Journal of Cardiology, 2004, 93, 679-684.	0.7	117
39	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. Journal of the American College of Cardiology, 2011, 58, 2550-2583.	1.2	114
40	Paclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus. Journal of the American College of Cardiology, 2008, 51, 708-715.	1.2	106
41	Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet, The, 2018, 392, 1530-1540.	6.3	103
42	Left Main Coronary Artery Stenosis. JACC: Cardiovascular Interventions, 2013, 6, 1219-1230.	1.1	101
43	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2013, 82, E266-355.	0.7	97
44	4-Step Protocol for Disparities in STEMIÂCare and Outcomes in Women. Journal of the American College of Cardiology, 2018, 71, 2122-2132.	1.2	97
45	Comparison of Percutaneous Versus Surgical Revascularization of Severe Unprotected Left Main Coronary Stenosis in Matched Patients. American Journal of Cardiology, 2008, 101, 169-172.	0.7	96
46	Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockade. American Journal of Cardiology, 2000, 86, 780-782.	0.7	93
47	Relation Between Lesion Characteristics and Risk With Percutaneous Intervention in the Stent and Glycoprotein IIb/IIIa Era. Circulation, 1999, 100, 1971-1976.	1.6	88
48	Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the facilitated intervention with enhanced reperfusion speed to stop events (FINESSE) trial. American Heart Journal, 2004, 147, 684.	1.2	88
49	Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation. Journal of the American College of Cardiology, 2005, 45, 1201-1205.	1.2	88
50	Characterization of Post-Operative Risk Associated With Prior Drug-Eluting Stent Use. JACC: Cardiovascular Interventions, 2009, 2, 542-549.	1.1	76
51	Benefit of Facilitated Percutaneous Coronary Intervention in High-Risk ST-Segment Elevation Myocardial Infarction Patients Presenting to Nonpercutaneous Coronary Intervention Hospitals. JACC: Cardiovascular Interventions, 2009, 2, 917-924.	1.1	76
52	Pronounced Benefit of Coronary Stenting and Adjunctive Platelet Glycoprotein IIb/IIIa Inhibition in Complex Atherosclerotic Lesions. Circulation, 2000, 102, 28-34.	1.6	69
53	Analysis and Comparison of Operator-Specific Outcomes in Interventional Cardiology. Circulation, 1996, 93, 431-439.	1.6	66
54	Detailed Analysis of Bone Marrow From Patients With Ischemic Heart Disease and Left Ventricular Dysfunction. Circulation Research, 2014, 115, 867-874.	2.0	65

#	Article	IF	CITATIONS
55	Granulocyte colony stimulating factor in patients with large acute myocardial infarction: Results of a pilot dose-escalation randomized trial. American Heart Journal, 2006, 152, 1051.e9-1051.e14.	1.2	63
56	Importance of Abnormal Chloride Homeostasis in Stable Chronic Heart Failure. Circulation: Heart Failure, 2016, 9, e002453.	1.6	61
57	Long-term Outcome of Transient, Uncomplicated In-Laboratory Coronary Artery Closure. Circulation, 1995, 91, 2733-2741.	1.6	60
58	1-Year Survival in a Randomized Trial of Facilitated Reperfusion. JACC: Cardiovascular Interventions, 2009, 2, 909-916.	1.1	59
59	Measures to Reduce Radiation in a Modern Cardiac Catheterization Laboratory. Circulation: Cardiovascular Interventions, 2014, 7, 447-455.	1.4	59
60	Is traditionally defined complete revascularization needed for patients with multivessel disease treated by elective coronary angioplasty?. Journal of the American College of Cardiology, 1993, 22, 1289-1297.	1.2	58
61	Long-Term Safety and Efficacy of Paclitaxel-Eluting Stents. JACC: Cardiovascular Interventions, 2011, 4, 530-542.	1.1	57
62	Reduction in Myocardial Infarct Size by Basic Fibroblast Growth Factor After Temporary Coronary Occlusion in a Canine Model. Circulation, 1996, 94, 1927-1933.	1.6	57
63	Cause of Death Within 30 Days of Percutaneous Coronary Intervention in an Era of Mandatory Outcome Reporting. Journal of the American College of Cardiology, 2013, 62, 409-415.	1.2	56
64	The State of the Absorb BioresorbableÂScaffold. JACC: Cardiovascular Interventions, 2017, 10, 2349-2359.	1.1	55
65	Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial. European Heart Journal, 2008, 29, 1625-1634.	1.0	54
66	Long-Term Mortality in Patients With Radiation-Associated Coronary Artery Disease Treated With Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	46
67	Predictors of Successful Hybrid-Approach Chronic Total Coronary Artery OcclusionÂStenting. JACC: Cardiovascular Interventions, 2017, 10, 1089-1098.	1.1	43
68	Percutaneous Intervention for Myocardial Infarction After Noncardiac Surgery. Journal of the American College of Cardiology, 2016, 68, 329-338.	1.2	42
69	Long-Term Impact of Drug-Eluting Stents Versus Bare-Metal Stents on All-Cause Mortality. Journal of the American College of Cardiology, 2008, 52, 1041-1048.	1.2	41
70	Impact of lean six sigma process improvement methodology on cardiac catheterization laboratory efficiency. Cardiovascular Revascularization Medicine, 2016, 17, 95-101.	0.3	40
71	Enoxaparin in Primary and Facilitated Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2010, 3, 203-212.	1.1	37
72	β-Blockers Before Percutaneous Coronary Intervention Do Not Attenuate Postprocedural Creatine Kinase Isoenzyme Rise. Circulation, 2001, 104, 2685-2688.	1.6	36

#	Article	IF	CITATIONS
73	Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stenting. American Journal of Cardiology, 2002, 89, 937-940.	0.7	35
74	Characteristics, Predictors, and Mechanisms of Thrombosis inÂCoronary Bioresorbable Scaffolds. JACC: Cardiovascular Interventions, 2017, 10, 2363-2371.	1.1	35
75	Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. Journal of the American College of Cardiology, 2002, 40, 669-675.	1.2	34
76	Real-world bare metal stenting: Identification of patients at low or very low risk of 9-month coronary revascularization. Catheterization and Cardiovascular Interventions, 2004, 63, 135-140.	0.7	33
77	Associations Between Cardiac Troponin, Mechanism of Myocardial Injury, and Longâ€Term Mortality After Noncardiac Vascular Surgery. Journal of the American Heart Association, 2017, 6, .	1.6	33
78	Immediate sealing of arterial puncture sites after cardiac catheterization and coronary interventions: Initial U.S. feasibility trial using the Duett vascular closure device. Catheterization and Cardiovascular Interventions, 2000, 50, 96-102.	0.7	32
79	Safety of "Bridging―With Eptifibatide for Patients With Coronary Stents Before Cardiac and Non-Cardiac Surgery. American Journal of Cardiology, 2012, 110, 485-490.	0.7	32
80	High-Risk Coronary Atheroma. Journal of the American College of Cardiology, 2014, 63, 1134-1140.	1.2	32
81	Utility of Glycated Hemoglobin for Assessment of Glucose Metabolism in Patients With ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2016, 117, 749-753.	0.7	30
82	Evaluation of Infarct-Related Coronary Artery Patency and Microcirculatory Function After Facilitated Percutaneous Primary Coronary Angioplasty. JACC: Cardiovascular Interventions, 2010, 3, 1284-1291.	1.1	29
83	Prognostic Value of Estimated Functional Capacity Incremental to Cardiac Biomarkers in Stable Cardiac Patients. Journal of the American Heart Association, 2014, 3, e000960.	1.6	29
84	Recognized Obstructive Sleep Apnea is Associated With Improved Inâ€Hospital Outcomes After ST Elevation Myocardial Infarction. Journal of the American Heart Association, 2017, 6, .	1.6	29
85	Excimer Laser Atherectomy in Percutaneous Coronary Intervention: A Contemporary Review. Cardiovascular Revascularization Medicine, 2021, 25, 75-85.	0.3	29
86	Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. American Journal of Cardiology, 2002, 89, 1209-1211.	0.7	28
87	Management of drug eluting stent inâ€stent restenosis: A systematic review and metaâ€analysis. Catheterization and Cardiovascular Interventions, 2016, 87, 1080-1091.	0.7	28
88	Association of Glycemic Control With Mortality in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2014, 7, 503-509.	1.4	26
89	Clinical, Angiographic, and Procedural Correlates of Acute, Subacute, and Late Absorb Scaffold Thrombosis. JACC: Cardiovascular Interventions, 2017, 10, 1809-1815.	1.1	26
90	Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study. Journal of Invasive Cardiology, 2007, 19, 404-9.	0.4	26

#	Article	IF	CITATIONS
91	Drug-eluting versus bare-metal stents for treating saphenous vein grafts. American Heart Journal, 2009, 158, 637-643.	1.2	25
92	Prognostic Significance of Ischemic Mitral Regurgitation on Outcomes in Acute ST-Elevation Myocardial Infarction Managed by Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2017, 119, 20-26.	0.7	25
93	Comparison of three coronary stents: Clinical and angiographic outcome after elective placement in 134 consecutive patients. Catheterization and Cardiovascular Diagnosis, 1994, 33, 199-204.	0.7	21
94	Enhanced Prediction of Mortality After Percutaneous Coronary Intervention by Consideration of General and Neurological Indicators. JACC: Cardiovascular Interventions, 2011, 4, 442-448.	1.1	21
95	Clinical, Angiographic, and ProceduralÂCorrelates of VeryÂLateÂAbsorbÂScaffoldÂThrombosis. JACC: Cardiovascular Interventions, 2018, 11, 638-644.	1.1	20
96	Meta-Analysis of Angiographic Versus Intravascular Ultrasound Parameters of Drug-Eluting Stent Efficacy (from TAXUS IV, V, and VI). American Journal of Cardiology, 2007, 100, 621-626.	0.7	19
97	Drugâ€eluting stents versus bareâ€metal stents for treatment of bareâ€metal inâ€stent restenosis. Catheterization and Cardiovascular Interventions, 2010, 76, 257-262.	0.7	18
98	The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention. American Heart Journal, 2005, 150, 1190-1197.	1.2	17
99	Pilot Candidate Gene Analysis of Patients ≥60 Years Old With Aortic Stenosis Involving a Tricuspid Aortic Valve. American Journal of Cardiology, 2012, 110, 88-92.	0.7	16
100	Effects of long-term prednisone (≥5 mg) use on outcomes and complications of percutaneous coronary intervention. American Journal of Cardiology, 2004, 93, 1389-1390.	0.7	15
101	Relation of Polymorphisms in Five Genes to Long-Term Aortocoronary Saphenous Vein Graft Patency. American Journal of Cardiology, 2007, 99, 1087-1089.	0.7	15
102	Length of stay and longâ€ŧerm mortality following <scp>ST</scp> elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2015, 86, S1-7.	0.7	15
103	Bioresorbable Stents: Is This Where We Are Headed?. Progress in Cardiovascular Diseases, 2015, 58, 342-355.	1.6	15
104	Arteriotomy closure device safety after percutaneous coronary intervention in the direct thrombin inhibitor era: A comparative study. Catheterization and Cardiovascular Interventions, 2013, 81, 294-300.	0.7	14
105	Quantitative evaluation of local drug delivery using the InfusaSleeve catheter. , 1997, 42, 102-108.		13
106	Genome-Wide Linkage Analysis of Large Multiple Multigenerational Families Identifies Novel Genetic Loci for Coronary Artery Disease. Scientific Reports, 2017, 7, 5472.	1.6	12
107	Impact of Platelet Glycoprotein IIb/IIIa Inhibition on the Paclitaxel-Eluting Stent in Patients With Stable or Unstable Angina Pectoris or Provocable Myocardial Ischemia (A TAXUS IV Substudy). American Journal of Cardiology, 2005, 96, 500-505.	0.7	11
108	The Weasel Clause: Excluding Patients From Door-to-Balloon Analyses. Journal of the American College of Cardiology, 2010, 56, 1763.	1.2	11

#	Article	IF	CITATIONS
109	LightTyperâ"¢ platform for high-throughput clinical genotyping. Expert Review of Molecular Diagnostics, 2005, 5, 457-471.	1.5	10
110	Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions. Catheterization and Cardiovascular Interventions, 2017, 89, E64-E74.	0.7	10
111	Operational Efficiency and Productivity Improvement Initiatives in a LargeÂCardiacÂCatheterization Laboratory. JACC: Cardiovascular Interventions, 2018, 11, 329-338.	1.1	10
112	Eroding the Denominator. Journal of the American College of Cardiology, 2012, 60, 789-790.	1.2	9
113	Utilization and outcomes of polytetrafluoroethylene covered stents in patients with coronary artery perforation and coronary artery aneurysm: Single center 15â€year experience. Catheterization and Cardiovascular Interventions, 2019, 94, 555-561.	0.7	9
114	Readmissions in ST-Elevation Myocardial Infarction and Cardiogenic Shock (from Nationwide) Tj ETQq0 0 0 rgBT	/Oyerlock	10 ₉ Tf 50 542
115	A Critical Analysis of Clinical Outcomes Reported in Stem Cell Trials for Acute Myocardial Infarction: Some Thoughts for Design of Future Trials. Current Atherosclerosis Reports, 2013, 15, 341.	2.0	8
116	Genome-Wide Linkage Scan Identifies Two Novel Genetic Loci for Coronary Artery Disease: In GeneQuest Families. PLoS ONE, 2014, 9, e113935.	1.1	8
117	Renin-Angiotensin System Antagonists in Patients Without Left Ventricular Dysfunction After Percutaneous Intervention for ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2015, 116, 508-514.	0.7	8
118	Analysis of causal effect of <i>APOA5</i> variants on premature coronary artery disease. Annals of Human Genetics, 2018, 82, 437-447.	0.3	8
119	Long-Term Outcomes of Patients With Mediastinal Radiation–Associated Coronary Artery Disease Undergoing Coronary Revascularization With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting. Circulation, 2020, 142, 1399-1401.	1.6	8
120	Outcomes of Early Coronary Angiography or Revascularization After Cardiac Surgery. Annals of Thoracic Surgery, 2021, 111, 1494-1501.	0.7	8
121	"Crying Fire in a Theater―or a "Confirmatory Sighting?â€âŽâŽEditorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology Journal of the American College of Cardiology, 2007. 50. 268-269.	1.2	7
122	Survival Prediction Models for Coronary Intervention: Strategic Decision Support. Annals of Thoracic Surgery, 2014, 97, 522-528.	0.7	7
123	Management of coronary chronic total occlusion. Cleveland Clinic Journal of Medicine, 2017, 84, 27-38.	0.6	7
124	Creation of a large-scale genetic data bank for cardiovascular association studies. American Heart Journal, 2005, 150, 500-506.	1.2	6
125	Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomy—a propensity-adjusted analysis. American Heart Journal, 2006, 151, 1031.e1-1031.e6.	1.2	6
126	Implementation of a Myocardial Perfusion Imaging Risk Algorithm to Inform Appropriate Downstream Invasive Testing and Treatment. Circulation: Cardiovascular Imaging, 2021, 14, e011984.	1.3	5

#	Article	IF	CITATIONS
127	Comparison of long-term survival following non–Q-wave creatine kinase elevation after percutaneous coronary intervention in patients discharged on a beta blocker versus those not so treated. American Journal of Cardiology, 2002, 89, 751-753.	0.7	4
128	Angiographic predictors of adverse outcomes after percutaneous coronary intervention in patients with radiation associated coronary artery disease. Catheterization and Cardiovascular Interventions, 2019, 94, E104-E110.	0.7	4
129	Association of adoption of transradial access for percutaneous coronary intervention in ST elevation myocardial infarction with doorâ€ŧoâ€balloon time. Catheterization and Cardiovascular Interventions, 2020, 96, E165-E173.	0.7	4
130	Bioresorbable stents: The future of interventional cardiology?. Cleveland Clinic Journal of Medicine, 2016, 83, S18-S23.	0.6	4
131	The role of ISCHEMIA in stable ischemic heart disease. Cleveland Clinic Journal of Medicine, 2020, 87, 401-409.	0.6	4
132	GuardWire emboli protection device is associated with improved myocardial perfusion grade in saphenous vein graft intervention. American Heart Journal, 2004, 148, 1003-1006.	1.2	3
133	Frequency and factors associated with inappropriate for intervention cardiac catheterization laboratory activation. Cardiovascular Revascularization Medicine, 2016, 17, 219-224.	0.3	3
134	Fractional flow reserve guided percutaneous coronary intervention results in reduced ischemic myocardium and improved outcomes. Catheterization and Cardiovascular Interventions, 2018, 92, 692-700.	0.7	3
135	Comparison of Long-Term Clinical Outcomes After Drug-Eluting Stenting in Blacks-vs-Whites. American Journal of Cardiology, 2019, 124, 1179-1185.	0.7	3
136	Restenosis, Statistics, and Reasonable Inferences. Journal of the American College of Cardiology, 2006, 47, 470-471.	1.2	2
137	Percutaneous Left Main Invention. JACC: Cardiovascular Interventions, 2010, 3, 642-647.	1.1	2
138	Fantom Bioresorbable Scaffold. JACC: Cardiovascular Interventions, 2017, 10, 1839-1840.	1.1	2
139	Coronary Tortuosity and Long-Term Post-Stent Risk. JACC: Cardiovascular Interventions, 2021, 14, 1019-1020.	1.1	2
140	Intravascular ultrasound predictors of long-term outcomes following ABSORB bioresorbable scaffold implantation: A pooled analysis of the ABSORB III and ABSORB Japan trials. Journal of Cardiology, 2021, 78, 224-229.	0.8	2
141	Abstract 17910: Patients with Newly Diagnosed Diabetes Have Comparable Long Term Mortality with Known Diabetics After ST Segment Elevation Myocardial Infarction. Circulation, 2014, 130, .	1.6	2
142	First human randomized trial of G-CSF stem cell mobilization to treat large acute myocardial infarction—preliminary results of a pilot study. International Congress Series, 2004, 1262, 364-367.	0.2	1
143	Stent choice and the hidden consequences of cost savings. Nature Reviews Cardiology, 2012, 9, 559-560.	6.1	1
144	Do We Know the Best Treatment for In-Stent Restenosis Via Network Meta-Analysis (NMA)?. JACC: Cardiovascular Interventions, 2015, 8, 395-397.	1.1	1

#	Article	IF	CITATIONS
145	CLINICAL, ANGIOGRAPHIC AND PROCEDURAL CORRELATES OF ABSORB SCAFFOLD THROMBOSIS: A MATCHED MULTICENTER REGISTRY ANALYSIS. Journal of the American College of Cardiology, 2017, 69, 964.	1.2	1
146	Walking the right path: the story of bioresorbable stents. Journal of Thoracic Disease, 2017, 9, 1786-1788.	0.6	1
147	CTO Coronary Perforations. JACC: Cardiovascular Interventions, 2019, 12, 1913-1914.	1.1	1
148	How Should We Treat Patients With Silent Myocardial Ischemia?. JACC: Cardiovascular Interventions, 2019, 12, 242-244.	1.1	1
149	Endâ€stage renal disease as an independent risk factor for inâ€hospital mortality after coronary drugâ€eluting stenting: Understanding and modeling the risk. Catheterization and Cardiovascular Interventions, 2020, 98, 246-254.	0.7	1
150	Successful modeling of long term outcomes in endâ€stage renal disease patients undergoing percutaneous coronary intervention with drugâ€eluting stents. Catheterization and Cardiovascular Interventions, 2021, 98, 208-214.	0.7	1
151	Incidence, treatment, and outcomes of acute myocardial infarction following transcatheter or surgical aortic valve replacement. Catheterization and Cardiovascular Interventions, 2021, , .	0.7	1
152	Quantitative evaluation of local drug delivery using the InfusaSleeve catheter. Catheterization and Cardiovascular Diagnosis, 1997, 42, 102-108.	0.7	1
153	Unprotected Left Main Coronary Artery Disease: Management in the Post NOBLE and EXCEL Era. Interventional Cardiology Review, 2017, 12, 92.	0.7	1
154	Abstract 16161: Bone Marrow Characteristics are Associated With Changes in Infarct Size Following STEMI: A Biorepository Evaluation From the CCTRN TIME Trial. Circulation, 2014, 130, .	1.6	1
155	Outcomes of Interventional Management of Coronary Artery Disease in Kidney Transplant Recipients. Transplantation Proceedings, 2022, 54, 663-663.	0.3	1
156	Presence of Diabetes Does Not Matter for Percutaneous Coronary Intervention Outcomes With Simple Coronary Lesions. Journal of the American College of Cardiology, 2014, 63, 2119-2120.	1.2	0
157	Role of Revascularization to Improve Left Ventricular Function. Heart Failure Clinics, 2015, 11, 203-214.	1.0	0
158	Bioresorbable Vascular Scaffolds. JACC: Cardiovascular Interventions, 2017, 10, 796-797.	1.1	0
159	Assessing the Likelihood of Chronic TotalÂOcclusion Percutaneous Coronary Intervention Procedural Success. JACC: Cardiovascular Interventions, 2019, 12, 343-345.	1.1	0
160	Prediabetic Patient Outcomes 8 to 15 Years After Drug-Eluting Coronary Stenting. American Journal of Cardiology, 2021, 149, 21-26.	0.7	0
161	Abstract 17075: Outcomes in Radiation Associated Cardiac Disease Patients that present with Coronary Artery Disease: Comparison between PCI and CABG. Circulation, 2014, 130, .	1.6	0
162	Abstract 10954: Clinical and Angiographic Predictors of Adverse Outcomes After Percutaneous Coronary Intervention in Patients With Radiation Associated Coronary Artery Disease. Circulation, 2015, 132, .	1.6	0

#	Article	IF	CITATIONS
163	Abstract 14566: Mild Elevation in Cardiac Troponin T is Independently Associated With Long-Term Mortality After Intermediate or High-Risk Vascular Surgery. Circulation, 2015, 132, .	1.6	0
164	Feasibility of transradial primary percutaneous coronary intervention for <scp>STEMI</scp> complicated by cardiac arrest. Catheterization and Cardiovascular Interventions, 2022, 99, 1363-1365.	0.7	0
165	Incremental progress? The roles of direct stenting and routine troponin measurement after percutaneous coronary intervention. Journal of Invasive Cardiology, 2002, 14, 171-2.	0.4	0
166	Plaque that makes a patient vulnerable. Journal of Invasive Cardiology, 2004, 16, 401.	0.4	0